{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:04:17Z","timestamp":1790229857116,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare adverse event reporting patterns for seven Alzheimer\u2019s disease (AD) drugs (aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, and memantine) using the FDA Adverse Event Reporting System (FAERS), and to explore potential reporting signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS reports from the first quarter of 2004 to the second quarter of 2026 were retrospectively analyzed. Adverse events were coded using MedDRA version 28.1 preferred terms (PTs) and system organ classes (SOCs). Disproportionality signals were detected using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma-Poisson shrinker (MGPS). PT-level signals were additionally controlled using Benjamini\u2013Hochberg false discovery rate correction. Drug-level comparisons, sex- and age-stratified analyses, time-to-onset (TTO) analysis, and Weibull distribution fitting were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 39,301 valid reports involving the seven AD drugs were included. Reports were more frequent among women (52.3%, n = 20,537) and patients aged \u226565 years. Anti-A\u03b2 monoclonal antibodies showed concentrated reporting signals in nervous system disorders, with amyloid related imaging abnormalities (ARIA) related events as the core PT-level signal. Donanemab and lecanemab were also associated with prominent infusion-related reaction signals. Conventional symptomatic drugs demonstrated broader multi-system reporting patterns: donepezil and galantamine were mainly associated with cholinergic cardiovascular and fall-related signals; rivastigmine with administration-site reactions and fall-related events; and memantine with confusional state, agitation, dizziness, and somnolence. Several PT-level signals were not listed in the reviewed prescribing information and were annotated as potential reporting signals. Sex- and age-stratified analyses showed broadly consistent PT-level spectra. TTO analyses revealed heterogeneous onset patterns among different drug and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study utilized FAERS data to compare adverse event reporting signals for seven anti-AD drugs. Distinct reporting profiles were observed across drugs, and several potential ADE signals, including potential unlabeled reporting signals, were identified. These findings may support pharmacovigilance surveillance and hypothesis generation, but should be interpreted as reporting associations rather than evidence of causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1955230","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:43:22Z","timestamp":1790228602000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Disproportionality analysis of adverse event signals associated with seven Alzheimer\u2019s drugs: insights from the FAERS database"],"prefix":"10.3389","volume":"17","author":[{"given":"Kai","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical University","place":["Bengbu, China"]},{"name":"School of Pharmacy, Bengbu Medical University","place":["Bengbu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical University","place":["Bengbu, China"]},{"name":"School of Pharmacy, Bengbu Medical University","place":["Bengbu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingti","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical University","place":["Bengbu, China"]},{"name":"School of Pharmacy, Bengbu Medical University","place":["Bengbu, China"]},{"name":"State Key Laboratory of Neurology and Oncology Drug Development","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"afad205","DOI":"10.1093\/ageing\/afad205","article-title":"Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis","volume":"52","author":"Ahuja","year":"2023","journal-title":"Age Ageing"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 alzheimer's disease facts and figures","volume":"20","author":"Author Anonymous","year":"2024","journal-title":"Alzheimer's and Dementia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early alzheimer's disease","volume":"9","author":"Budd","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1105620","DOI":"10.3389\/fnagi.2023.1105620","article-title":"Sex and gender considerations in Alzheimer\u2019s disease: the Women\u2019s brain project contribution","volume":"15","author":"Castro-Aldrete","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.14283\/jpad.2022.34","article-title":"Aducanumab: appropriate use recommendations update","volume":"9","author":"Cummings","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e12465","DOI":"10.1002\/trc2.12465","article-title":"Alzheimer's disease drug development pipeline: 2024","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimer's and Dementia Transl. Res. and Clin. Interventions"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2023","journal-title":"Front. Drug Saf. Regul."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1326784","DOI":"10.3389\/fnins.2024.1326784","article-title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","volume":"18","author":"Doran","year":"2024","journal-title":"Front. Neurosci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/14737175.2025.2527211","article-title":"An overview of the rivastigmine 13.3 mg\/24h transdermal patch as a treatment option for alzheimer's disease","volume":"25","author":"Fortea","year":"2025","journal-title":"Expert Rev. Neurother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/14740338.2025.2576520","article-title":"Tolerability of rivastigmine transdermal patch in patients with alzheimer's disease: a narrative review","volume":"25","author":"Garc\u00eda","year":"2026","journal-title":"Expert Opin. Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Dementia forecasting collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1561020","DOI":"10.3389\/fphar.2025.1561020","article-title":"A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases","volume":"16","author":"Hu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1522058","DOI":"10.3389\/fphar.2025.1522058","article-title":"A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of alzheimer's disease: alzheimer's association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2092","DOI":"10.1212\/wnl.0000000000201019","article-title":"Incidence of amyloid-related imaging abnormalities in patients with alzheimer disease treated with Anti-\u03b2-Amyloid immunotherapy: a meta-analysis","volume":"99","author":"Jeong","year":"2022","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1593989","DOI":"10.3389\/fphar.2025.1593989","article-title":"Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system","volume":"16","author":"Kong","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"qfag014","DOI":"10.1093\/sexmed\/qfag014","article-title":"Safety profile and signal detection of tadalafil: a real-world analysis based on the food and drug adverse event reporting system","volume":"14","author":"Li","year":"2026","journal-title":"Sex. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.12793\/tcp.2025.33.e19","article-title":"Sex differences in efficacy\/safety of anti-amyloid-beta monoclonal antibodies for the treatment of alzheimer's disease","volume":"33","author":"Lim","year":"2025","journal-title":"Transl. Clin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/nejmoa2100708","article-title":"Donanemab in early alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jclinepi.2021.06.022","article-title":"High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study","volume":"138","author":"Mouffak","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/TCRM.S323387","article-title":"Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review","volume":"17","author":"Ruangritchankul","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"B29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/1567205019666220120112301","article-title":"Comparative efficacy and acceptability of cholinesterase inhibitors and memantine based on dosage in patients with vascular cognitive impairment: a network meta-analysis","volume":"19","author":"Shi","year":"2022","journal-title":"Curr. Alzheimer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"Jama"},{"key":"B33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","article-title":"Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1439115","DOI":"10.3389\/fphar.2024.1439115","article-title":"Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1804602","DOI":"10.3389\/fphar.2026.1804602","article-title":"Comparative risk of arrhythmias associated with systemic antifungal agents: a disproportionality analysis of the FAERS database","volume":"17","author":"Yang","year":"2026","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4235\/agmr.21.0079","article-title":"Cardiovascular complications of acetylcholinesterase inhibitors in patients with alzheimer's disease: a narrative review","volume":"25","author":"Young","year":"2021","journal-title":"Ann. Geriatr. Med. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1955230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:43:23Z","timestamp":1790228603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1955230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":38,"alternative-id":["10.3389\/fphar.2026.1955230"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1955230","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1955230"}}